Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
VPS34-INI
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/25/2020
AZD2014
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/25/2020
NVP-BHG712
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/25/2020
Pixatimod
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/24/2020
11b
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/19/2020
11a
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/19/2020
MT326102
Potential treatment - theoretical effect Experimental Vaccine Jun/17/2020
MT326715
Potential treatment - theoretical effect Experimental Vaccine Jun/17/2020
LY2228820
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
R-428
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
L-796568
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
NCO-700
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
SMN-C3
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
GS-9901
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
GW-803430
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
SAX-187
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
YM-161514
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
Dutacatib
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
KC-11404
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020
NNC-090026
Potential treatment - pre-clinical evidence Experimental Antiviral Jun/16/2020